Burrows Scott L sold $2.3M of SYRE
Burrows Scott L (Chief Financial Officer) sold 25,000 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $90.47 ($89.07–$93.57, $2.26M total) across 6 trades over 2026-09-30 to 2026-10-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The transaction is a primary disclosure; its modest size limits market impact but is noteworthy for a micro‑cap.
Market read
Insider sell may prompt short‑term price dip; investors will watch subsequent trading for confirmation.
What to watch
The CFO retains a sizable stake; the sale may be for personal liquidity rather than lack of confidence.
Background
Form 4 filings provide the first public disclosure of insider transactions. This sale is the first report of the CFO's recent divestiture.
Ticker impact
CFO Burrows Scott L sold 25,000 shares for $2.26M via a 10b5‑1 plan, reducing his stake to 79,762 shares.
likely downward pressure as the market prices in the insider sell
A $2.3M sale by a senior officer is material for a micro‑cap biotech and can prompt traders to trim exposure.
Market effects
May raise concerns for other biotech stocks with recent insider sales.
Limited to U.S. biotech investors.
Low
Counterpoint
The sale could be routine under a pre‑arranged plan, not reflecting company outlook.
Key entities
- companySpyre Therapeutics, Inc.
Biotech firm (ticker SYRE) whose CFO disclosed a $2.3M share sale.
- personBurrows Scott L
Chief Financial Officer of Spyre Therapeutics, executing a 10b5‑1 sale.
